EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSCAFG00020012042
Gene Symbol: PIK3R2
3 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSCAFG00020015140
Gene Symbol: PIK3R3
3 Cross references
276 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSCAFG00020006765
Gene Symbol: PIK3R5
3 Cross references
255 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSCAFG00020008330
Gene Symbol: PLA2G5
3 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSCAFG00020012657
Gene Symbol: PLA2G7
3 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSCAFG00020024118
Gene Symbol: PLA2G10
3 Cross references
250 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSCAFG00020025345
Gene Symbol: GART
3 Cross references
247 Possible Orthologues:

Plasminogen

Ensembl ID : ENSCAFG00020018797
Gene Symbol: PLG
2 Cross references
269 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSCAFG00020023486
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSCAFG00020001700
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSCAFG00020023594
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSCAFG00020002561
Gene Symbol: PDGFB
3 Cross references
263 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).